|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-4-3
|
|
pubmed:abstractText |
Anti-B-cell immunotherapy has been used with success in adults with posttransplant B-cell lymphoproliferative disease (PTLD), but such treatment has rarely been reported in children. We report the outcome of anti-CD20 antibody (rituximab) therapy for Epstein-Barr virus (EBV)-associated PTLD in six pediatric liver transplant recipients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0277-2116
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
389-93
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11930095-Adolescent,
pubmed-meshheading:11930095-Antibodies, Monoclonal,
pubmed-meshheading:11930095-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:11930095-Antineoplastic Agents,
pubmed-meshheading:11930095-B-Lymphocytes,
pubmed-meshheading:11930095-Child,
pubmed-meshheading:11930095-Child, Preschool,
pubmed-meshheading:11930095-Epstein-Barr Virus Infections,
pubmed-meshheading:11930095-Humans,
pubmed-meshheading:11930095-Infant,
pubmed-meshheading:11930095-Liver Transplantation,
pubmed-meshheading:11930095-Lymphoproliferative Disorders
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
|
|
pubmed:affiliation |
Unit of Hepatology, Department of Pediatrics, and Laboratory of Pathology, Bicêtre University Hospital, Paris, France.
|
|
pubmed:publicationType |
Journal Article
|
